A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2017
At a glance
- Drugs MGA 012 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors MacroGenics
- 25 Oct 2017 According to an Incyte Corporation media release, data from dose escalation portion have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting 2017.
- 25 Oct 2017 According to an Incyte Corporation media release, enrollment in the dose escalation portion of the trial has been completed.
- 02 Aug 2017 According to a MacroGenics media release, patients are being enrolled in the dose escalation segment of the study and expects to define a target dose and schedule soon.